Cite
Sun Y, Zhao N, Wang H, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent . J Cancer. 2017;8(14):2774-2784doi: 10.7150/jca.18731.
Sun, Y., Zhao, N., Wang, H., Wu, Q., Han, Y., Liu, Q., Wu, M., Liu, Y., Kong, F., Wang, H., Sun, Y., Sun, D., Jing, L., Tang, G., Hu, Y., Xiao, D., Luo, H., Han, Y., & Peng, Y. (2017). CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent . Journal of Cancer, 8(14), 2774-2784. https://doi.org/10.7150/jca.18731
Sun, Yinghui, et al. "CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent ." Journal of Cancer vol. 8,14 (2017): 2774-2784. doi: https://doi.org/10.7150/jca.18731
Sun Y, Zhao N, Wang H, Wu Q, Han Y, Liu Q, Wu M, Liu Y, Kong F, Wang H, Sun Y, Sun D, Jing L, Tang G, Hu Y, Xiao D, Luo H, Han Y, Peng Y. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent . J Cancer. 2017 Aug 23;8(14):2774-2784. doi: 10.7150/jca.18731. eCollection 2017. PMID: 28928866; PMCID: PMC5604209.
Copy
Download .nbib